The glucagon receptor/GLP-1 receptor dual agonist reduces weight, visceral fat, and liver fat.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/dual-incretin-agonist-survodutide-benefits-liver-phase-3-2026a1000j5d?src=rss
Author :
Publish date : 2026-06-08 21:00:00
Copyright for syndicated content belongs to the linked Source.
